2Q2022 Polen Capital Global Growth Commentary
The conditions during the second quarter of the year have largely been a continuation of what we experienced during the first quarter, with a long list of exogenous factors continuing to weigh on the market, including persistent inflation, tightening monetary policy, and ongoing supply chain issues.
During the quarter, consumer discretionary, information technology, and health care companies have been broadly punished amid a backdrop of rising rates, valuation resets, and waning consumer confidence, which impacted the Polen Capital Global Growth Fund.
The three smallest absolute detractors for the period in the Fund were ADP, an American provider of human resources management software and services, the Australian global biotech leader CSL, and Starbucks. The three largest absolute detractors were Alphabet, Amazon, and Align Technology – a global orthodontic medical device company.
The recent market drawdown seems indiscriminate, but Polen Capital expect fundamentals to eventually come back into focus. When Polen Capital combine their ongoing expectations for mid-teens earnings per share growth from the Fund with what they believe are now very reasonable valuations, Polen Capital are optimistic despite the many exogenous factors that are weighing on the market today.
Read the Polen Capital Global Growth 2Q2022 update
Established in 1979, Polen Capital is a high conviction growth investment manager with offices in the US and UK. Polen has been dedicated to serving investors by providing concentrated portfolios of the highest-quality companies for more than three decades. The firm’s established team manages US$71 billion in total assets and their longest-running flagship investment strategy has delivered on average double digit annual returns for more than 30 years.
This post was contributed by a representative of Montgomery Investment Management Pty Limited (AFSL No. 354564). The principal purpose of this post is to provide factual information and not provide financial product advice. Additionally, the information provided is not intended to provide any recommendation or opinion about any financial product. Any commentary and statements of opinion however may contain general advice only that is prepared without taking into account your personal objectives, financial circumstances or needs. Because of this, before acting on any of the information provided, you should always consider its appropriateness in light of your personal objectives, financial circumstances and needs and should consider seeking independent advice from a financial advisor if necessary before making any decisions. This post specifically excludes personal advice.
